KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Shares Issued (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Shares Issued for 13 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued rose 319.79% year-over-year to $1.3 million, compared with a TTM value of $2.8 million through Dec 2025, changed N/A, and an annual FY2025 reading of $2.8 million, changed N/A over the prior year.
  • Shares Issued was $1.3 million for Q4 2025 at Travere Therapeutics, up from -$2.7 million in the prior quarter.
  • Across five years, Shares Issued topped out at $188.0 million in Q4 2023 and bottomed at -$2.7 million in Q2 2025.
  • Average Shares Issued over 5 years is $12.3 million, with a median of $903500.0 recorded in 2022.
  • The sharpest move saw Shares Issued soared 6211.55% in 2023, then tumbled 307.04% in 2025.
  • Year by year, Shares Issued stood at -$1.3 million in 2021, then surged by 333.57% to $3.0 million in 2022, then skyrocketed by 6211.55% to $188.0 million in 2023, then plummeted by 100.3% to -$571000.0 in 2024, then surged by 319.79% to $1.3 million in 2025.
  • Business Quant data shows Shares Issued for TVTX at $1.3 million in Q4 2025, -$2.7 million in Q2 2025, and $4.2 million in Q1 2025.